Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3445668 | 0.90 | PARP1 (0.63) | PARP1ALOX15ATMTDP1L3MBTL1 | |
| SCHEMBL9353671 | 0.87 | PARP1 (0.55) | PARP1ALOX15ATMTDP1L3MBTL1 | |
| SCHEMBL3177794 | 0.86 | PARP1 (0.59) | PARP1ALOX15ATMTDP1L3MBTL1 | |
| SCHEMBL9126956 | 0.86 | ATM (0.67) | ALOX15ATMTDP1L3MBTL1LMNA | |
| SCHEMBL3173817 | 0.86 | PARP1 (0.68) | PARP1ALOX15ATMTDP1L3MBTL1 | |
| SCHEMBL31514279 | 0.84 | ATM (0.71) | PARP1ALOX15ATMTDP1L3MBTL1 | |
| SCHEMBL1133114 | 0.84 | ATM (0.71) | PARP1ALOX15ATMTDP1L3MBTL1 | |
| SCHEMBL3444927 | 0.84 | PARP1 (0.65) | PARP1ALOX15ATMTDP1L3MBTL1 | |
| SCHEMBL7488057 | 0.83 | MAPK1 (0.64) | PARP1ALOX15ATMTDP1L3MBTL1 | |
| SCHEMBL8437706 | 0.83 | SRD5A2 (0.64) | PARP1ALOX15ATMTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| US-7345050-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-03-18 | — | — | US | disclosed |
| US-20040077642-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | US | disclosed |
| EP-1373266-A2 | (DIAZOLO-PYRIDINYL)-PYRIMIDINES FOR USE IN TREATMENT OF CNS DISORDERS AND DIABETES | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002065979-A2 | (DIAZOLO-PYRIDINYL)-PYRIMIDINES FOR USE IN TREATMENT OF CNS DISORDERS AND DIABETES | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
| EP-0425930-B1 | Process for the preparation of symmetrical diarylacetylenes | BAYER AG (DE) | 1994-09-28 | — | — | EP | disclosed |
| US-5185454-A | Reacting aryl bromide with acetylene in presence of palladium catalyst and nitrogen-containing heterocyclic base | BAYER AKTIENGESELLSCHAFT (DE) | 1993-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077642-A1 | Pyrimidine compounds | TYMP, DPYD, TYMS | PARP1 379/4885ALOX15 1387/4885ATM 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.